The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Breast cancer: an up‐to‐date review and future perspectives
Open accessAbstract
Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is associated with many risk factors, including genetic and hereditary predisposition. Breast cancers are highly heterogeneous. Treatment strategies for breast cancer vary by molecular features, including activation of human epidermal growth factor receptor 2 (HER2), hormonal receptors (estrogen receptor [ER] and progesterone receptor [PR]), gene mutations (e.g., mutations of breast cancer 1/2 [ BRCA1/2 ] and phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha [ PIK3CA ]) and markers of the immune microenvironment (e.g., tumor‐infiltrating lymphocyte [TIL] and programmed death‐ligand 1 [PD‐L1]). Early‐stage breast cancer is considered curable, for which local‐regional therapies (surgery and radiotherapy) are the cornerstone, with systemic therapy given before or after surgery when necessary. Preoperative or neoadjuvant therapy, including targeted drugs or immune checkpoint inhibitors, has become the standard of care for most early‐stage HER2‐positive and triple‐negative breast cancer, followed by risk‐adapted post‐surgical strategies. For ER‐positive early breast cancer, endocrine therapy for 5‐10 years is essential. Advanced breast cancer with distant metastases is currently considered incurable. Systemic therapies in this setting include endocrine therapy with targeted agents, such as CDK4/6 inhibitors and phosphoinositide 3‐kinase (PI3K) inhibitors for hormone receptor‐positive disease, anti‐HER2 targeted therapy for HER2‐positive disease, poly(ADP‐ribose) polymerase inhibitors for BRCA1/2 mutation carriers and immunotherapy currently for part of triple‐negative disease. Innovation technologies of precision medicine may guide individualized treatment escalation or de‐escalation in the future. In this review, we summarized the latest scientific information and discussed the future perspectives on breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Johnston, S. R. D., Hegg, R., Im, S.-A., Park, I. H., Burdaeva, O., Kurteva, G., Press, M. F., Tjulandin, S., Iwata, H., Simon, S. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7824 · Cited by 165
RetractedSung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350 · cited 1×
“The IMpassion130 trial randomized 902 patients with metastatic TNBC who were not treated in the metastatic setting to receive the PDL1 inhibitor, atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel [55, 192, 193].”
BackgroundGoldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Self-citationPembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270 · cited 1×
“00055), as shown by the phase III KEYNOTE-522 study at the primary analysis for pCR [54].”
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
Self-citationvon Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 6×
“Novel biomarkers that have shown promising data in selecting patients for immunotherapy, such as circulating tumor DNA (ctDNA), TILs and expression of MHC-II complex, warrant further study in this field.”
BackgroundInfluentialAllemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X.-S., Bannon, F., Ahn, J. V., Johnson, C. J., Bonaventure, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62038-9 · Cited by 2,614
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
EBCTCG (Early Breast Cancer Trialists' Collaborative Group) (2014) · The Lancet · doi:10.1016/s0140-6736(14)60488-8 · Cited by 2,254
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F., van’t Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.-Y., Brain, E., Causeret, S., DeLorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 1,994
Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening
Pisano, E. D., Gatsonis, C., Hendrick, E., Yaffe, M., Baum, J. K., Acharyya, S., Conant, E. F., Fajardo, L. L., Bassett, L., D'Orsi, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052911 · Cited by 1,940
Giuliano, A. E., Ballman, K. V., McCall, L., Beitsch, P. D., Brennan, M. B., Kelemen, P. R., Ollila, D. W., Hansen, N. M., Whitworth, P. W., Blumencranz, P. W., et al. (2017) · JAMA · doi:10.1001/jama.2017.11470 · Cited by 1,912
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
Whelan, T. J., Pignol, J.-P., Levine, M. N., Julian, J. A., MacKenzie, R., Parpia, S., Shelley, W., Grimard, L., Bowen, J., Lukka, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0906260 · Cited by 1,878
Donker, M., van Tienhoven, G., Straver, M. E., Meijnen, P., van de Velde, C. J. H., Mansel, R. E., Cataliotti, L., Westenberg, A. H., Klinkenbijl, J. H. G., Orzalesi, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70460-7 · Cited by 1,871
Meta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32531-9 · Cited by 1,796
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Oeffinger, K. C., Fontham, E. T. H., Etzioni, R., Herzig, A., Michaelson, J. S., Shih, Y.-C. T., Walter, L. C., Church, T. R., Flowers, C. R., LaMonte, S. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.12783 · Cited by 1,653
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Boughey, J. C. (2013) · JAMA · doi:10.1001/jama.2013.278932 · Cited by 1,588
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Berg, W. A. (2008) · JAMA · doi:10.1001/jama.299.18.2151 · Cited by 1,526
(2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,520
Cancer incidence and mortality in China, 2016
Zheng, R., Zhang, S., Zeng, H., Wang, S., Sun, K., Chen, R., Li, L., Wei, W., & He, J. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.02.002 · Cited by 1,494
Kuehn, T., Bauerfeind, I., Fehm, T., Fleige, B., Hausschild, M., Helms, G., Lebeau, A., Liedtke, C., Minckwitz, G. V., Nekljudova, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70166-9 · Cited by 1,485
Haviland, J. S., Owen, J. R., Dewar, J. A., Agrawal, R. K., Barrett, J., Barrett-Lee, P. J., Dobbs, H. J., Hopwood, P., Lawton, P. A., Magee, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70386-3 · Cited by 1,470
Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703643 · Cited by 1,411
Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji372 · Cited by 1,339
Regional Nodal Irradiation in Early-Stage Breast Cancer
Whelan, T. J., Olivotto, I. A., Parulekar, W. R., Ackerman, I., Chua, B. H., Nabid, A., Vallis, K. A., White, J. R., Rousseau, P., Fortin, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415340 · Cited by 1,294
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112651 · Cited by 1,274
Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30689-8 · Cited by 1,216
Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
Mauri, D., Pavlidis, N., & Ioannidis, J. P. A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji021 · Cited by 1,200
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,175
Self-citationKuhl, C. K., Schrading, S., Leutner, C. C., Morakkabati-Spitz, N., Wardelmann, E., Fimmers, R., Kuhn, W., & Schild, H. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.4960 · Cited by 1,147
Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women
Breast Cancer Association Consortium (2021) · New England Journal of Medicine · doi:10.1056/nejmoa1913948 · Cited by 1,136
The 2019 World Health Organization classification of tumours of the breast
Tan, P. H., Ellis, I., Allison, K., Brogi, E., Fox, S. B., Lakhani, S., Lazar, A. J., Morris, E. A., Sahin, A., Salgado, R., et al. (2020) · Histopathology · doi:10.1111/his.14091 · Cited by 1,097
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Murray Brunt, A., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Alhasso, A., Bloomfield, D. J., Chan, C., Churn, M., Cleator, S., Coles, C. E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30932-6 · Cited by 1,084
Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31953-x · Cited by 1,083 · cited 1×
“Similar results were observed in the IMpassion 031 trial, which showed the addition of atezolizumab to nab-paclitaxel followed by doxorubicin-cyclophosphamide increased pCR in early TNBC [164].”
Resultvon Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Overall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707056 · Cited by 997
Key steps for effective breast cancer prevention
Britt, K. L., Cuzick, J., & Phillips, K.-A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0266-x · Cited by 992
Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30863-0 · Cited by 922
Breast cancer intrinsic subtype classification, clinical use and future trends.
Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., & Shi, B. (2015) · Europe PMC (PubMed Central) · Cited by 921
Caudle, A. S., Yang, W. T., Krishnamurthy, S., Mittendorf, E. A., Black, D. M., Gilcrease, M. Z., Bedrosian, I., Hobbs, B. P., DeSnyder, S. M., Hwang, R. F., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0094 · Cited by 920
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Loi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P. A., Lacroix-Triki, M., Joensuu, H., Dieci, M. V., Badve, S., Demaria, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01010 · Cited by 893
Gianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S.-A., Pedrini, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00163-7 · Cited by 880
Control of BRCA2 Cellular and Clinical Functions by a Nuclear Partner, PALB2
Xia, B., Sheng, Q., Nakanishi, K., Ohashi, A., Wu, J., Christ, N., Liu, X., Jasin, M., Couch, F. J., & Livingston, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.022 · Cited by 861
Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., Senn, H. J., Winer, E. P., Gnant, M., Aebi, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 821
Self-citationA Population-Based Study of Genes Previously Implicated in Breast Cancer
Hu, C., Hart, S. N., Gnanaolivu, R., Huang, H., Lee, K. Y., Na, J., Gao, C., Lilyquist, J., Yadav, S., Boddicker, N. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2005936 · Cited by 816
Zhang, Y., Chen, H., Mo, H., Hu, X., Gao, R., Zhao, Y., Liu, B., Niu, L., Sun, X., Yu, X., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.010 · Cited by 783
Self-citationRobson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779
Self-citationLoibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., Albain, K. S., Rugo, H. S., Ellis, M., Shapira, I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406281 · Cited by 753
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404037 · Cited by 749
Miles, D., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C., Xu, B., Wardley, A., Kaen, D., Andrade, L., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.801 · Cited by 734
Self-citationAdjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Eiermann, W., Paepke, S., Appfelstaedt, J., Llombart-Cussac, A., Eremin, J., Vinholes, J., Mauriac, L., Ellis, M., Lassus, M., Chaudri-Ross, H. A., et al. (2001) · Annals of Oncology · doi:10.1023/a:1013128213451 · Cited by 713
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 676
Ellis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S., Chaudri Ross, H. A., von Kameke, A., Miller, W. R., Smith, I., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn309 · Cited by 653
Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, E. R., Wade, J. L., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0076 · Cited by 646
Burstein, H. J., Lacchetti, C., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Solky, A. J., Stearns, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01160 · Cited by 636
André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.011 · Cited by 624
Coles, C. E., Griffin, C. L., Kirby, A. M., Titley, J., Agrawal, R. K., Alhasso, A., Bhattacharya, I. S., Brunt, A. M., Ciurlionis, L., Chan, C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31145-5 · Cited by 611
Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00147 · Cited by 604
Martin, M., Holmes, F. A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S. K. L., Mansi, J., Barrios, C. H., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30717-9 · Cited by 585
Self-citationPiccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574
Lin, N. U., Borges, V., Anders, C., Murthy, R. K., Paplomata, E., Hamilton, E., Hurvitz, S., Loi, S., Okines, A., Abramson, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00775 · Cited by 544
Yardley, D. A., Noguchi, S., Pritchard, K. I., Burris, H. A., Baselga, J., Gnant, M., Hortobagyi, G. N., Campone, M., Pistilli, B., Piccart, M., et al. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0060-1 · Cited by 522
Duffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.017 · Cited by 522
Kuhl, C., Weigel, S., Schrading, S., Arand, B., Bieling, H., König, R., Tombach, B., Leutner, C., Rieber-Brambs, A., Nordhoff, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0839 · Cited by 501
Cuzick, J., Sestak, I., Bonanni, B., Costantino, J. P., Cummings, S., DeCensi, A., Dowsett, M., Forbes, J. F., Ford, L., LaCroix, A. Z., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60140-3 · Cited by 495
Emens, L. A., Adams, S., Barrios, C. H., Diéras, V., Iwata, H., Loi, S., Rugo, H. S., Schneeweiss, A., Winer, E. P., Patel, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.355 · Cited by 475
Poggio, F., Bruzzone, M., Ceppi, M., Pondé, N. F., La Valle, G., Del Mastro, L., de Azambuja, E., & Lambertini, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy127 · Cited by 468
Pisano, E. D., Hendrick, R. E., Yaffe, M. J., Baum, J. K., Acharyya, S., Cormack, J. B., Hanna, L. A., Conant, E. F., Fajardo, L. L., Bassett, L. W., et al. (2008) · Radiology · doi:10.1148/radiol.2461070200 · Cited by 464
Boughey, J. C., Ballman, K. V., Le-Petross, H. T., McCall, L. M., Mittendorf, E. A., Ahrendt, G. M., Wilke, L. G., Taback, B., Feliberti, E. C., & Hunt, K. K. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001375 · Cited by 457
Meattini, I., Marrazzo, L., Saieva, C., Desideri, I., Scotti, V., Simontacchi, G., Bonomo, P., Greto, D., Mangoni, M., Scoccianti, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00650 · Cited by 443
Overgaard, M., Nielsen, H. M., & Overgaard, J. (2007) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2007.02.001 · Cited by 438
Autier, P., Boniol, M., LaVecchia, C., Vatten, L., Gavin, A., Hery, C., & Heanue, M. (2010) · BMJ · doi:10.1136/bmj.c3620 · Cited by 412
Litton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2098 · Cited by 412
Xu, B., Yan, M., Ma, F., Hu, X., Feng, J., Ouyang, Q., Tong, Z., Li, H., Zhang, Q., Sun, T., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30702-6 · Cited by 402
Self-citationBuys, S. S., Sandbach, J. F., Gammon, A., Patel, G., Kidd, J., Brown, K. L., Sharma, L., Saam, J., Lancaster, J., & Daly, M. B. (2017) · Cancer · doi:10.1002/cncr.30498 · Cited by 399
Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial
Jagsi, R., Chadha, M., Moni, J., Ballman, K. V., Laurie, F., Buchholz, T. A., Giuliano, A. E., & Haffty, B. G. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5838 · Cited by 393
Harbeck, N., Rastogi, P., Martin, M., Tolaney, S. M., Shao, Z. M., Fasching, P. A., Huang, C. S., Jaliffe, G. G., Tryakin, A., Goetz, M. P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.015 · Cited by 381
Ellis, M. J., Suman, V. J., Hoog, J., Goncalves, R., Sanati, S., Creighton, C. J., DeSchryver, K., Crouch, E., Brink, A., Watson, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.4406 · Cited by 366
Andre, F., Ismaila, N., Allison, K. H., Barlow, W. E., Collyar, D. E., Damodaran, S., Henry, N. L., Jhaveri, K., Kalinsky, K., Kuderer, N. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00069 · Cited by 365
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients
Möbus, V. (2016) · Breast Care · doi:10.1159/000444004 · Cited by 354
Montemurro, F., Delaloge, S., Barrios, C. H., Wuerstlein, R., Anton, A., Brain, E., Hatschek, T., Kelly, C. M., Peña-Murillo, C., Yilmaz, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.020 · Cited by 349
Rugo, H. S., Lerebours, F., Ciruelos, E., Drullinsky, P., Ruiz-Borrego, M., Neven, P., Park, Y. H., Prat, A., Bachelot, T., Juric, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00034-6 · Cited by 345
Freedman, R. A., Gelman, R. S., Anders, C. K., Melisko, M. E., Parsons, H. A., Cropp, A. M., Silvestri, K., Cotter, C. M., Componeschi, K. P., Marte, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01511 · Cited by 341
Sardanelli, F., Podo, F., Santoro, F., Manoukian, S., Bergonzi, S., Trecate, G., Vergnaghi, D., Federico, M., Cortesi, L., Corcione, S., et al. (2011) · Investigative Radiology · doi:10.1097/rli.0b013e3181f3fcdf · Cited by 337
Loibl, S., Marmé, F., Martin, M., Untch, M., Bonnefoi, H., Kim, S.-B., Bear, H., McCarthy, N., Melé Olivé, M., Gelmon, K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03639 · Cited by 326
Sestak, I., Buus, R., Cuzick, J., Dubsky, P., Kronenwett, R., Denkert, C., Ferree, S., Sgroi, D., Schnabel, C., Baehner, F. L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5524 · Cited by 318
Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence
Li, T., Mello-Thoms, C., & Brennan, P. C. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3947-0 · Cited by 309
Jiang, Y.-Z., Liu, Y., Xiao, Y., Hu, X., Jiang, L., Zuo, W.-J., Ma, D., Ding, J., Zhu, X., Zou, J., et al. (2021) · Cell Research · doi:10.1038/s41422-020-0375-9 · Cited by 298
Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E., Jacobs, S. A., Robert, N. J., Hopkins, J. O., O'Shaughnessy, J. A., Dang, C. T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.4147 · Cited by 294
Bradley, R., Braybrooke, J., Gray, R., Hills, R. K., Liu, Z., Pan, H., Peto, R., Dodwell, D., McGale, P., Taylor, C., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00758-0 · Cited by 290
Gao, J. J., Cheng, J., Bloomquist, E., Sanchez, J., Wedam, S. B., Singh, H., Amiri-Kordestani, L., Ibrahim, A., Sridhara, R., Goldberg, K. B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30804-6 · Cited by 289
Lord, S. J., Lei, W., Craft, P., Cawson, J. N., Morris, I., Walleser, S., Griffiths, A., Parker, S., & Houssami, N. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.06.007 · Cited by 281
Tolaney, S. M., Guo, H., Pernas, S., Barry, W. T., Dillon, D. A., Ritterhouse, L., Schneider, B. P., Shen, F., Fuhrman, K., Baltay, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00066 · Cited by 278
Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30164-0 · Cited by 270
Mayer, E. L., Dueck, A. C., Martin, M., Rubovszky, G., Burstein, H. J., Bellet-Ezquerra, M., Miller, K. D., Zdenkowski, N., Winer, E. P., Pfeiler, G., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30642-2 · Cited by 261
Polgár, C., Ott, O. J., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T., Lyczek, J., Guinot, J. L., Dunst, J., Miguelez, C. G., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30011-6 · Cited by 257
Sun, J., Meng, H., Yao, L., Lv, M., Bai, J., Zhang, J., Wang, L., Ouyang, T., Li, J., Wang, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3227 · Cited by 243
Cuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Cawthorn, S., Mansel, R. E., Loibl, S., Bonanni, B., Evans, D. G., & Howell, A. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32955-1 · Cited by 237
Sgroi, D. C., Carney, E., Zarrella, E., Steffel, L., Binns, S. N., Finkelstein, D. M., Szymonifka, J., Bhan, A. K., Shepherd, L. E., Zhang, Y., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt146 · Cited by 229
Wang, X., Wang, S.-S., Huang, H., Cai, L., Zhao, L., Peng, R.-J., Lin, Y., Tang, J., Zeng, J., Zhang, L.-H., et al. (2021) · JAMA · doi:10.1001/jama.2020.23370 · Cited by 229
Self-citationMa, F., Li, Q., Chen, S., Zhu, W., Fan, Y., Wang, J., Luo, Y., Xing, P., Lan, B., Li, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.6179 · Cited by 228
Self-citationLoibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw197 · Cited by 227
Hurvitz, S. A., Martin, M., Press, M. F., Chan, D., Fernandez-Abad, M., Petru, E., Rostorfer, R., Guarneri, V., Huang, C.-S., Barriga, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1425 · Cited by 227
Brunt, A. M., Wheatley, D., Yarnold, J., Somaiah, N., Kelly, S., Harnett, A., Coles, C., Goodman, A., Bahl, A., Churn, M., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.02.027 · Cited by 225
Sparano, J. A., Zhao, F., Martino, S., Ligibel, J. A., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9271 · Cited by 222
Chan, A., Moy, B., Mansi, J., Ejlertsen, B., Holmes, F. A., Chia, S., Iwata, H., Gnant, M., Loibl, S., Barrios, C. H., et al. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.09.014 · Cited by 221
DeCensi, A., Puntoni, M., Guerrieri-Gonzaga, A., Caviglia, S., Avino, F., Cortesi, L., Taverniti, C., Pacquola, M. G., Falcini, F., Gulisano, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01779 · Cited by 218
Rimawi, M., Ferrero, J.-M., de la Haba-Rodriguez, J., Poole, C., De Placido, S., Osborne, C. K., Hegg, R., Easton, V., Wohlfarth, C., Arpino, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7863 · Cited by 217
Ki67 assessment in breast cancer: an update
Penault-Llorca, F., & Radosevic-Robin, N. (2017) · Pathology · doi:10.1016/j.pathol.2016.11.006 · Cited by 216
Yu, K.-D., Ye, F.-G., He, M., Fan, L., Ma, D., Mo, M., Wu, J., Liu, G.-Y., Di, G.-H., Zeng, X.-H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2965 · Cited by 213
Bartlett, J. M. S., Sgroi, D. C., Treuner, K., Zhang, Y., Ahmed, I., Piper, T., Salunga, R., Brachtel, E. F., Pirrie, S. J., Schnabel, C. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz289 · Cited by 203
Blok, E. J., Kroep, J. R., Meershoek-Klein Kranenbarg, E., Duijm-de Carpentier, M., Putter, H., van den Bosch, J., Maartense, E., van Leeuwen-Stok, A. E., Liefers, G.-J., Nortier, J. W. R., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx134 · Cited by 200
Golshan, M., Cirrincione, C. T., Sikov, W. M., Berry, D. A., Jasinski, S., Weisberg, T. F., Somlo, G., Hudis, C., Winer, E., & Ollila, D. W. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001417 · Cited by 196
Behavioral Risk Factors in Breast Cancer: Can Risk Be Modified?
McTiernan, A. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-326 · Cited by 193
Dowsett, M., Sestak, I., Regan, M. M., Dodson, A., Viale, G., Thürlimann, B., Colleoni, M., & Cuzick, J. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4258 · Cited by 193
Nitz, U., Gluz, O., Christgen, M., Kates, R. E., Clemens, M., Malter, W., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4358-6 · Cited by 189
Regan, M. M., Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3171 · Cited by 183
Kuemmel, S., Heil, J., Rueland, A., Seiberling, C., Harrach, H., Schindowski, D., Lubitz, J., Hellerhoff, K., Ankel, C., Graßhoff, S.-T., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000004572 · Cited by 181
Xu, B., Zhang, Q., Zhang, P., Hu, X., Li, W., Tong, Z., Sun, T., Teng, Y., Wu, X., Ouyang, Q., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01562-9 · Cited by 179
Self-citationTee, S. R., Devane, L., Evoy, D., Rothwell, J. R., Geraghty, J., Prichard, R. S., & McDermott, E. W. M. (2018) · British journal of surgery · doi:10.1002/bjs.10986 · Cited by 167
Mamounas, E. P., Bandos, H., Lembersky, B. C., Jeong, J.-H., Geyer, C. E., Rastogi, P., Fehrenbacher, L., Graham, M. L., Chia, S. K., Brufsky, A. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30621-1 · Cited by 167
Tjan‐Heijnen, V. C. G., van Hellemond, I. E. G., Peer, P. G. M., Swinkels, A. C. P., Smorenburg, C. H., van der Sangen, M. J. C., Kroep, J. R., de Graaf, H., Honkoop, A. H., Erdkamp, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30600-9 · Cited by 163
Yan, M., Ouyang, Q., Sun, T., Niu, L., Yang, J., Li, L., Song, Y., Hao, C., Chen, Z., Orlandi, A., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00716-6 · Cited by 161
Lluch, A. M., Barrios, C. H., Torrecillas, L., Ruíz‐Borrego, M., Bines, J., Segalla, J. G. M., Zotano, Á. G., García-Sáenz, J. Á., Torres, R., de la Haba-Rodríguez, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00904 · Cited by 160
Zumsteg, Z. S., Morrow, M., Arnold, B. B., Zheng, J., Zhang, Z., Robson, M. E., Traina, T. A., McCormick, B. L., Powell, S. N., & Ho, A. Y. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3011-9 · Cited by 154
Pagani, O., Francis, P. A., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M. A., Láng, I., Gómez, H., Tondini, C. A., Pinotti, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01967 · Cited by 149
Nitz, U. A., Gluz, O., Clemens, M., Malter, W., Reimer, T., Nuding, B., Aktas, B., Stefek, A., Pollmanns, A., Lorenz-Salehi, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00028 · Cited by 144
Mannino, M., & Yarnold, J. R. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.05.002 · Cited by 138
Bardia, A., Hurvitz, S. A., DeMichele, A. M., Clark, A. S., Zelnak, A. B., Yardley, D. A., Karuturi, M. S., Sanft, T. B., Blau, S. H., Hart, L. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2114 · Cited by 136
Tan, V. K. M., Goh, B. K. P., Fook-Chong, S. M. C., Khin, L., Wong, W., & Yong, W. S. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21911 · Cited by 135
Johnston, S. R. D., Hegg, R., Im, S., Park, I. H., Burdaeva, O. N., Kurteva, G. P., Press, M. F., Tjulandin, S., Iwata, H., Simon, S. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01894 · Cited by 123
Colleoni, M. A., Luo, W., Karlsson, P., Chirgwin, J. H., Aebi, S. P., Jérusalem, G., Neven, P., Hitre, E., Graas, M.-P., Simoncini, E., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30715-5 · Cited by 120
Ruhstaller, T., Giobbie‐Hurder, A., Colleoni, M. A., Jensen, M., Ejlertsen, B., de Azambuja, E., Neven, P., Láng, I., Jakobsen, E. H., Gladieff, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00440 · Cited by 111
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
Royce, M., Osgood, C., Mulkey, F., Bloomquist, E., Pierce, W. F., Roy, A., Kalavar, S., Ghosh, S., Philip, R., Rizvi, F., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02742 · Cited by 111
Geng, C., Chen, X., Pan, X., & Li, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162605 · Cited by 110
Ng, A. K., Garber, J. E., Diller, L., Birdwell, R. L., Feng, Y., Neuberg, D. S., Silver, B., Fisher, D. C., Marcus, K. J., & Mauch, P. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5732 · Cited by 108
Lin, N., Pegram, M. D., Sahebjam, S., Ibrahim, N. K., Fung, A., Cheng, A., Nicholas, A., Kirschbrown, W. P., & Kumthekar, P. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02822 · Cited by 100
Golshan, M. A., Cirrincione, C., Sikov, W. M., Carey, L., Berry, D. A., Overmoyer, B. A., Henry, N. L., Somlo, G., Port, E. R., Burstein, H. J., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4006-6 · Cited by 93
Peairs, K. S., Choi, Y., Stewart, R. W., & Sateia, H. F. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.02.004 · Cited by 91
Yuan, P., Hu, X., Sun, T., Li, W., Zhang, Q., Cui, S., Cheng, Y., Ouyang, Q., Wang, X., Chen, Z., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.02.002 · Cited by 89
Self-citationKriege, M., Brekelmans, C. T. M., Boetes, C., Muller, S. H., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Rutgers, E. J. T., de Koning, H. J., et al. (2006) · Cancer · doi:10.1002/cncr.21863 · Cited by 81
Gebruers, N., Verbelen, H., Vrieze, T. D., Coeck, D., & Tjalma, W. A. A. (2015) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2015.01.014 · Cited by 76
Hua, X., Bi, X.-W., Zhao, J.-L., Shi, Y.-X., Lin, Y., Wu, Z.-Y., Zhang, Y.-Q., Zhang, L.-H., Zhang, A.-Q., Huang, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3435 · Cited by 75
Self-citationMoore, K. M. H., Sweeney, K., Wilson, M., Goldberg, J., Buchanan, C. L., Tan, L. K., Liberman, L., Turner, R. R., Lagios, M. D., Cody, H. S., et al. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9414-8 · Cited by 72
Zhang, P., Sun, T., Zhang, Q., Yuan, Z., Jiang, Z., Wang, X. J., Cui, S., Teng, Y., Hu, X., Yang, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30088-8 · Cited by 68
Self-citationAssociation of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer
Pohl‐Rescigno, E., Hauke, J., Loibl, S., Möbus, V. J., Denkert, C., Fasching, P. A., Kayali, M., Ernst, C., Weber‐Lassalle, N., Hanusch, C. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0007 · Cited by 67
Hurvitz, S. A., Saura, C., Oliveira, M., Trudeau, M., Moy, B., Delaloge, S., Gradishar, W. J., Kim, S., Haley, B., Ryvo, L., et al. (2021) · The Oncologist · doi:10.1002/onco.13830 · Cited by 65
Endocrine Therapy in Early Breast Cancer
Krauss, K., & Stickeler, E. (2020) · Breast Care · doi:10.1159/000509362 · Cited by 64
Xu, B., Li, W., Zhang, Q., Shao, Z., Li, Q., Wang, X., Li, H., Sun, T., Yin, Y., Zheng, H. Y., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05728-w · Cited by 56
Self-citationBreast MRI for Women With Hereditary Cancer Risk
Robson, M. E., & Offit, K. (2004) · JAMA · doi:10.1001/jama.292.11.1368 · Cited by 55
ASCO-CAP Guidelines for Breast Predictive Factor Testing
Hammond, M. E. H. (2011) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e31822a8eac · Cited by 52
Xu, B., Sun, T., Zhang, Q., Zhang, P., Yuan, Z., Jiang, Z., Wang, X., Cui, S., Teng, Y., Hu, X., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.600 · Cited by 51
Self-citationKorzets, Y., Fyles, A., Shepshelovich, D., Amir, E., & Goldvaser, H. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05209-9 · Cited by 48
Chai, Y., Chen, Y., Zhang, D., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020323 · Cited by 48
Mayer, E. L., Fesl, C., Hlauschek, D., Garcia-Estevez, L., Burstein, H. J., Zdenkowski, N., Wette, V., Miller, K. D., Balic, M., Mayer, I. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01918 · Cited by 44
Tumour‐positive sentinel node findings in patients with ductal carcinoma in situ
Leidenius, M., Salmenkivi, K., von Smitten, K., & Heikkilä, P. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20581 · Cited by 42
Shah, R., & O'Regan, R. M. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-70197-4_2 · Cited by 17
Marta, G. N., Barrett, J., Porfírio, G. J. M., Martimbianco, A. L. C., Bevilacqua, J. L. B., Poortmans, P. M., & Riera, R. (2019) · Reports of Practical Oncology & Radiotherapy · doi:10.1016/j.rpor.2019.01.009 · Cited by 15
Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum
Dent, R. A., & Rugo, H. S. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30747-6 · Cited by 13
Tagliaferri, L., Lancellotta, V., Colloca, G. A., Marazzi, F., Masiello, V., Garganese, G., Kovács, G., Valentini, V., & Gambacorta, M. A. (2020) · Journal of Oncology · doi:10.1155/2020/3928976 · Cited by 12
Wu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., Xu, Y., & Xie, Y. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05483-7 · Cited by 10
Disagreements Between FDA and its Oncologic Drugs Advisory Committee (ODAC)
Verduzco, A. A., & Yeboah, K. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-020-00194-4 · Cited by 9
Cited by
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Metadata
- Authors
- Hong, R., & Xu, B.
- Venue
- Cancer Communications
- Published
- 2022-09-08
- Volume
- 42
- Issue
- 10
- Pages
- 913-936
- ISSN
- 1000-467X (ISSN-L)
- 2523-3548
- OpenAlex
- W4295082389
- Cited by
- 407
- References
- 199
- FWCI
- 26.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.